3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
14
Thoracic
4
Gastrointestinal
2
CNS
2
Sarcoma
1
Head & Neck
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
163
Breast Neoplasms
162
Carcinoma, Non-Small-Cell Lung
60
Melanoma
44
Ovarian Neoplasms
42
Colorectal Neoplasms
37
Carcinoma, Renal Cell
36
Squamous Cell Carcinoma of Head and Neck
33
Pancreatic Neoplasms
29
Stomach Neoplasms
28
Neoplasm Metastasis
27
Uterine Cervical Neoplasms
24
Neoplasms
24
Endometrial Neoplasms
24
Lung Neoplasms
19
Head and Neck Neoplasms
19
Esophageal Neoplasms
18
Carcinoma, Transitional Cell
18
Carcinoma, Hepatocellular
16
Urinary Bladder Neoplasms
14
Small Cell Lung Carcinoma
14
Prostatic Neoplasms
14
Parkinson Disease 4, Autosomal Dominant Lewy Body
13
Sarcoma
10
Mesothelioma
9
Kidney Neoplasms
9
Cholangiocarcinoma
9
Carcinoma, Ovarian Epithelial
9
Carcinoma, Merkel Cell
9
Fallopian Tube Neoplasms
8
Interventions
Nivolumab
2
Cyclophosphamide
2
tislelizumab
1
spartalizumab
1
pembrolizumab
1
montanide ISA 51
1
glembatumumab vedotin
1
fludarabine phosphate
1
entinostat
1
cemiplimab
1
Toll-Like Receptor 1
1
Surveys and Questionnaires
1
Specimen Handling
1
Rose Bengal
1
Magnetic Resonance Spectroscopy
1
Ipilimumab
1
Interleukin-2
1
Interleukin-13
1
Focus Groups
1
Fluorodeoxyglucose F18
1
Cryosurgery
1
CTLA-4 Antigen
1
CR011-vcMMAE
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uveal Melanoma
×
pembrolizumab
×
Breast
×
Clear all
NCT05576077
2025-03-10
STARLING
Turnstone Biologics, Corp.
Phase 1
Terminated
31 enrolled